Cargando…

Statins and adrenal androgen levels in prostate cancer: A new twist

Detalles Bibliográficos
Autor principal:	Mostaghel, Elahe A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318847/ https://www.ncbi.nlm.nih.gov/pubmed/34280785 http://dx.doi.org/10.1016/j.ebiom.2021.103494

Ejemplares similares

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors
por: Mostaghel, Elahe A., et al.
Publicado: (2012)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
por: Mostaghel, Elahe A
Publicado: (2014)

Steroid hormone synthetic pathways in prostate cancer
por: Mostaghel, Elahe A.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

A phosphorylation switch controls androgen biosynthesis in prostate cancer
por: Qiu, Yun
Publicado: (2023)

SecA—a New Twist in the Tale
por: Collinson, Ian
Publicado: (2016)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

A new role for statins in sepsis
por: Rachoin, Jean-Sebastien, et al.
Publicado: (2013)

Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer
por: Chinni, Sreenivasa R.
Publicado: (2021)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

New twist on the regulation of NKG2D ligand expression
por: Cerwenka, Adelheid
Publicado: (2009)

MuB gives a new twist to target DNA selection
por: Dramićanin, Marija, et al.
Publicado: (2013)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm
por: Zhou, Jianfu, et al.
Publicado: (2020)

Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
por: Jung, Jaeyoon, et al.
Publicado: (2015)

Androgen receptor variants: another twist in the plot
por: Macoska, Jill A.
Publicado: (2017)

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens
por: Dart, D. A., et al.
Publicado: (2011)

Recent progress in the physics of twisted particles
por: Zou, Liping, et al.
Publicado: (2023)

Commentary: A twist on pulmonary artery translocation
por: Backer, Carl L.
Publicado: (2021)

A tent pole twist on membrane ruffles
por: Philip, Reuben V., et al.
Publicado: (2018)

Protein translation controlled by the androgen receptor in prostate cancer: a novel therapeutic option?
por: Mirzakhani, Kimia, et al.
Publicado: (2020)

Congenital Adrenal Hyperplasia Causing Poor Response to Androgen Deprivation Therapy in Prostate Cancer
por: Kinaan, Mustafa, et al.
Publicado: (2020)

“New Twist” in Diabetes Care for HbA(1c) Reporting: “It Takes Two to Tango”!
por: Cefalu, William T., et al.
Publicado: (2012)

Statins as Inhibitors of Lung Cancer Bone Metastasis
por: Sarkar, Devanand
Publicado: (2017)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
por: Collier, Tony, et al.
Publicado: (2020)

Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer
por: Kondo, Takeshi, et al.
Publicado: (2016)

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells
por: Eide, Turid, et al.
Publicado: (2013)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Twisting tails exposed: the evidence for TCR conformational change
por: Levin, Susan E., et al.
Publicado: (2005)

Role of OATP Transporters in Steroid Uptake by Prostate Cancer Cells in Vivo
por: Green, Sean, et al.
Publicado: (2016)

Fibrinolysis and D-dimer in COVID-19: A Twisted Plot!
por: Magoon, Rohan, et al.
Publicado: (2022)

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer
por: Qian, Chen, et al.
Publicado: (2023)

Statins as modulators of bone formation
por: Edwards, Christopher J, et al.
Publicado: (2002)

TWIST2: A new candidate tumor suppressor in prostate cancer
por: Zhao, Chengxiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j4lj5mkj63fefahtjletcvma1i